Cas9 Base Editing for Low-Genotoxicity Lymphohematopoietic Engineering
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for genetic engineering of human immune cells, such as using CRISPR systems for gene editing, face challenges with inefficiency in precision alterations, high toxicity due to double-strand breaks, and potential oncogenic risks.
Innovation Solution
The use of base editor fusion proteins, comprising a deaminase domain fused to a Cas9 nickase domain with a base excision repair inhibitor domain, in conjunction with splice acceptor-splice donor gRNAs, to modify lymphohematopoietic cells, allowing for precise genetic modifications with reduced toxicity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If CRISPR systems are used to induce double-strand breaks for gene editing, then gene disruption efficiency is improved, but genotoxicity and oncogenic risks increase
Solution Approach 1:
The patent segments the DNA cutting function into two separate single-strand nicks instead of one double-strand break. By using two separate gRNAs that each create a single-strand nick, the system achieves gene disruption without the harmful effects of double-strand breaks, thereby reducing genotoxicity while maintaining editing efficiency
Solution Approach 2:
The patent introduces a base excision repair inhibitor as an intermediary component that blocks the cell's normal repair mechanisms. This inhibitor forces the cell to use alternative repair pathways that are less error-prone, reducing the formation of harmful mutations and genotoxicity while still achieving the desired genetic modification
2Adaptability or versatility
If multiple double-strand breaks are induced for multiplexed gene editing, then genetic engineering versatility is improved, but formation of gross chromosomal translocations increases
Solution Approach 1:
The patent applies segmentation by dividing each gene targeting event into two separate single-strand nicking events rather than one double-strand break. When performing multiplexed editing, this segmentation approach across multiple targets dramatically reduces the cumulative risk of chromosomal translocations while maintaining the ability to edit multiple genes simultaneously
Solution Approach 2:
The patent converts the potentially harmful double-strand break mechanism into a beneficial single-strand nicking approach. By using base excision repair inhibitors with nickase Cas9, the system transforms what would normally be a high-risk operation into a safe editing method that achieves multiplexed gene disruption without generating chromosomal translocations
3Manufacturing precision
If homology-directed repair is used for precise nucleotide alterations, then precision is improved, but editing efficiency decreases
Solution Approach 1:
The patent substitutes the mechanical homology-directed repair process with a biochemically-driven base editing mechanism. By using deaminase enzymes that directly chemically convert bases (e.g., C to U, then to T), the system achieves precise nucleotide alterations without requiring the complex and inefficient homology-directed repair machinery, thereby improving editing efficiency while maintaining precision
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach enables efficient and controlled multiplexed genetic engineering of human immune cells, achieving high conversion efficiencies of target bases with reduced off-target effects and genotoxicity, thereby enhancing the safety and precision of gene editing.
Implementation Method 1
a plasmid, mRNA, or protein encoding a base editor fusion protein comprising a deaminase domain fused to a Cas9 nickase domain
Implementation Method 2
wherein the nickase domain comprises a base excision repair inhibitor domain
Data Source
AI summary
Provided herein are methods and systems for targeted gene disruption (knock-out, missense mutation) and targeted gene knock-in in mammalian cells using base editors and guide RNAs (gRNAs) designed to target splice acceptor-splice donor sites. Also provided herein are universally acceptable genetically engineered cells comprising targeted disruptions in immunotherapy-related genes and comprising a CAR/TCR for therapeutic applications.


